New Content  edit
Get The App!

Loading the player...
What is the Current Standard of Care in Treating Polycythemia Vera (PV)?
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Rubin Mesa MD, Serge Verstovsek MD, Richard Silver MD, and Emily Knight R.N., O.C.N. provide their perspectives on the optimal use of cytoreductive therapies for PV. At present, there are no universal guidelines regarding the management of PV. Ruxolitinib was recently approved for PV patients who are resistant, refractory, or intolerant to hydroxyurea (HU).